EphA2 receptor is a key player in the metastatic onset of Ewing sarcoma

被引:52
作者
Garcia-Monclus, Silvia [1 ]
Lopez-Alemany, Roser [1 ]
Almacellas-Rabaiget, Olga [1 ]
Herrero-Martin, David [1 ,2 ]
Huertas-Martinez, Juan [1 ]
Lagares-Tena, Laura [1 ]
Alba-Pavon, Piedad [1 ]
Hontecillas-Prieto, Lourdes [2 ,3 ]
Mora, Jaume [4 ]
de Alava, Enrique [2 ,3 ]
Rello-Varona, Santi [1 ]
Giangrande, Paloma H. [5 ]
Tirado, Oscar M. [1 ,2 ,6 ]
机构
[1] Bellvitge Biomed Res Inst IDIBELL, Oncobell Program, Sarcoma Res Grp, Barcelona, Spain
[2] Carlos III Inst Hlth ISCIII, CIBERONC, Madrid, Spain
[3] Univ Seville, CSIC, Hosp Univ Virgen Rocio, Inst Biomed Sevilla IBIS,Lab Mol Pathol, Seville, Spain
[4] Hosp St Joan Deu, Dev Tumor Biol Lab, Barcelona, Spain
[5] Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA
[6] ICO, Barcelona, Spain
基金
美国国家卫生研究院;
关键词
EphA2; Ewing sarcoma; metastasis; ADAM19; ACQUIRED-RESISTANCE; CHEMICAL PROTEOMICS; TUMOR-SUPPRESSOR; CELL-MIGRATION; EXPRESSION; ROLES; PHOSPHORYLATION; INHIBITION; ACTIVATION; CAVEOLIN-1;
D O I
10.1002/ijc.31405
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ewing sarcoma (ES) is the second most common bone malignancy affecting children and young adults with poor prognosis due to high metastasis incidence. Our group previously described that EphA2, a tyrosine kinase receptor, promotes angiogenesis in Ewing sarcoma (ES) cells via ligand-dependent signaling. Now we wanted to explore EphA2 ligand-independent activity, controlled upon phosphorylation at S897 (p-EphA2(S897)), as it has been linked to metastasis in several malignancies. By reverse genetic engineering we explored the phenotypic changes after EphA2 removal or reintroduction. Gene expression microarray was used to identify key players in EphA2 signaling. Mice were employed to reproduce metastatic processes from orthotopically implanted engineered cells. We established a correlation between ES cells aggressiveness and p-EphA2(S897). Moreover, stable overexpression of EphA2 in low EphA2 expression ES cells enhanced proliferation and migration, but not a non-phosphorylable mutant (S987A). Consistently, silencing of EphA2 reduced tumorigenicity, migration and invasion in vitro, and lung metastasis incidence in experimental and spontaneous metastasis assays in vivo. A gene expression microarray revealed the implication of EphA2 in cell signaling, cellular movement and survival. ADAM19 knockdown by siRNA technology strongly reproduced the negative effects on cell migration observed after EphA2 silencing. Altogether, our results suggest that p-EphA2(S897) correlates with aggressiveness in ES, so blocking its function may be a promising treatment. What's new? Ewing sarcoma (ES) tumors, the second most frequent bone tumors among children and adolescents, are very aggressive and tend to recur and metastasize. Lack of knowledge regarding the molecular mechanisms that regulate this metastatic process is the main reason for the lack of efficient therapeutics. Here, by using gain- and loss-of-function experiments and in vitro and in vivo assays, the authors established a correlation between ES aggressiveness and phosphorylation of the tyrosine kinase receptor EphA2. Altogether, the findings suggest that blocking EphA2 expression or its function with drugs or genetic tools may be of use for the treatment of ES.
引用
收藏
页码:1188 / 1201
页数:14
相关论文
共 41 条
  • [1] EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer
    Amato, Katherine R.
    Wang, Shan
    Tan, Li
    Hastings, Andrew K.
    Song, Wenqiang
    Lovly, Christine M.
    Meador, Catherine B.
    Ye, Fei
    Lu, Pengcheng
    Balko, Justin M.
    Colvin, Daniel C.
    Cates, Justin M.
    Pao, William
    Gray, Nathanael S.
    Chen, Jin
    [J]. CANCER RESEARCH, 2016, 76 (02) : 305 - 318
  • [2] Bengtsson H., 2008, aroma. affymetrix: A generic framework in R for analyzing small to very large Affymetrix data sets in bounded memory
  • [3] CONTROLLING THE FALSE DISCOVERY RATE - A PRACTICAL AND POWERFUL APPROACH TO MULTIPLE TESTING
    BENJAMINI, Y
    HOCHBERG, Y
    [J]. JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY, 1995, 57 (01) : 289 - 300
  • [4] Inflammatory chemokines and metastasis-tracing the accessory
    Borsig, L.
    Wolf, M. J.
    Roblek, M.
    Lorentzen, A.
    Heikenwalder, M.
    [J]. ONCOGENE, 2014, 33 (25) : 3217 - 3224
  • [5] Proteolytic cleavage, trafficking, and functions of nuclear receptor tyrosine kinases
    Chen, Mei-Kuang
    Hung, Mien-Chie
    [J]. FEBS JOURNAL, 2015, 282 (19) : 3693 - 3721
  • [6] Role of ADAMS in Cancer Formation and Progression
    Duffy, Michael J.
    McKiernan, Eaclaoin
    O'Donovan, Norma
    McGowan, Patricia M.
    [J]. CLINICAL CANCER RESEARCH, 2009, 15 (04) : 1140 - 1144
  • [7] EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer
    Dunne, Philip D.
    Dasgupta, Sonali
    Blayney, Jaine K.
    McArt, Darragh G.
    Redmond, Keara L.
    Weir, Jessica-Anne
    Bradley, Conor A.
    Sasazuki, Takehiko
    Shirasawa, Senji
    Wang, Tingting
    Srivastava, Supriya
    Ong, Chee Wee
    Arthur, Ken
    Salto-Tellez, Manuel
    Wilson, Richard H.
    Johnston, Patrick G.
    Van Schaeybroeck, Sandra
    [J]. CLINICAL CANCER RESEARCH, 2016, 22 (01) : 230 - 242
  • [8] A Disintegrin and Metalloprotease (ADAM): Historical Overview of Their Functions
    Giebeler, Nives
    Zigrino, Paola
    [J]. TOXINS, 2016, 8 (04)
  • [9] Chemical Proteomics and Structural Biology Define EPHA2 Inhibition by Clinical Kinase Drugs
    Heinzlmeir, Stephanie
    Kudlinzki, Denis
    Sreeramulu, Sridhar
    Klaeger, Susan
    Gande, Santosh Lakshmi
    Linhard, Verena
    Wilhelm, Mathias
    Qiao, Huichao
    Helm, Dominic
    Ruprecht, Benjamin
    Saxena, Krishna
    Medard, Guillaume
    Schwalbe, Harald
    Kuster, Bernhard
    [J]. ACS CHEMICAL BIOLOGY, 2016, 11 (12) : 3400 - 3411
  • [10] Huber W, 2015, NAT METHODS, V12, P115, DOI [10.1038/NMETH.3252, 10.1038/nmeth.3252]